New eczema pill shows promise in Mid-Stage trial
Disease control
Not yet recruiting
This study tests an experimental pill called ENV-294 for adults with moderate-to-severe atopic dermatitis (eczema). About 200 participants will take either one of three doses of ENV-294 or a placebo daily for 12 weeks. Researchers will measure changes in eczema severity, symptoms…
Phase: PHASE2 • Sponsor: Enveda Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC